Clinical Trial

MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera

Study acronym: MITHRIDATE
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The trial will be a phase III, randomised-controlled, multi-centre, international, open-label trial consisting of ruxolitinib versus best available therapy, where best available therapy is a choice of interferon alpha, any formulation permitted (IFN) or hydroxycarbamide (HC), and which will be elected by the Investigator prior to randomisation.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2019-10-03; most recent amendment 2026-04-27.
Status change: Not Yet Recruiting → Recruiting 2020-03-27
Trial Details
NCT Number NCT04116502
Lead Sponsor University of Birmingham
Collaborators: Novartis, MPN Voice, National Cancer Institute, France
Conditions Polycythemia Vera
Enrollment 586 participants
Start Date 2019-10-25
Primary Completion 2028-10-31 (estimated)
Study Completion 2030-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-28